Validation of MdmX as a therapeutic target for reactivating p53 in tumors - Wikidata - wikimedia - TriplyDB

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

http://www.wikidata.org/entity/Q34209099

about

Chemical Variations on the p53 Reactivation Theme Tumorigenesis promotes Mdm4-S overexpression.Mdm proteins: critical regulators of embry ogenesis and homeostasis.MDM2 oligomers: antagonizers of the guardian of the genome.Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.MDM2, MDMX and p53 in oncogenesis and cancer therapy Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele Limiting the power of p53 through the ubiquitin proteasome pathway.MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53.Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress The effect of immunological status, in-vitro treatment and culture time on expression of eleven candidate reference genes in bovine blood mononuclear cells.Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicin Targeting Mdmx to treat breast cancers with wild-type p53.Reversible modulation of SIRT1 activity in a mouse strain.Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.MDM4 is a key therapeutic target in cutaneous melanoma.MDMX contains an autoinhibitory sequence element.Mdm2 and MdmX as Regulators of Gene Expression Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.Mouse models of Mdm2 and Mdm4 and their clinical implications.p53 as an intervention target for cancer and aging.Oncoprotein stabilization in brain tumors.Targeting p53-MDM2-MDMX loop for cancer therapy.MDM4 is a rational target for treating breast cancers with mutant p53.The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.Mouse modelling of the MDM2/MDMX-p53 signalling axis.Pharmacological activation of wild-type p53 in the therapy of leukemia.A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.Targeting MDM4 Splicing in Cancers.Exploiting the p53 Pathway for Therapy.MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation.BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo.Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.

P2860

Q26749008-F3A04E9B-EC83-4191-8526-79287C4FDA1B Q33688440-FD927976-D3EF-4ABC-8F89-5E5E541BF25E Q33712220-799C1C97-A623-4734-B7A3-390050B80EFE Q33922100-D02A1A28-3554-4BA2-B4D8-7B13EC0485A1 Q33998827-02759CBC-7A5E-4762-873B-DC9FC375C10B Q34166049-B5FBEED2-2787-4116-80E6-0F92D9389A18 Q34178921-17A60E2F-CCD8-42F4-991F-1E9BCBE88453 Q34273969-B1C4144C-D1C8-41F8-8E9F-A1C6CCFC2522 Q34342940-5EBD7CEE-B39A-45C2-9674-AC6EDB42EE0C Q34369223-F7200D22-2737-4387-B3B2-65EB4AE5523D Q34418111-A98133E5-0C4F-4B93-A407-F909EAD01DC4 Q34989369-5F12AF40-3F6F-4E02-B9F1-C8EB03727E23 Q35646655-78A908DF-CFAD-4DF4-A7AC-E48252E7EF43 Q36293819-4570B351-0F23-40E2-A3E7-65FAEE0297B0 Q36293839-51AE2BF4-E803-44A8-902E-690663DE6715 Q36300940-510D3256-B6FD-4BB1-A66E-E1B6C6BC73B2 Q36430692-01CF92AE-1DD9-484A-A18F-3F7F12214FEE Q36485161-B739EE12-3A6E-4731-B8F6-51ED5ADB4E3E Q36509629-C5509AA5-B117-4743-A133-8A9D3D066A42 Q37096987-9292BDB1-037B-4620-89D5-934B01ABFDF8 Q37276522-A355D7B2-8B28-435B-8FEE-604604531E3C Q38059700-038CAF31-372F-4200-8C7D-61F64A56753C Q38059739-61C652E6-7E2D-4A7C-B32A-0C4534C31618 Q38074740-93FAB02F-2657-4E20-8068-77F740F97354 Q38152454-7EECD9C2-51EE-439A-B1A0-D541195A3D28 Q38156100-B6E098AF-3C67-4427-B0AC-D431EFDC104E Q38247168-B377F88B-93A4-432D-A4D1-500E87B42EDC Q38720844-38B4E7F0-B251-41BA-A323-E7A38CEF6DD0 Q38756911-34115B54-3A6F-4B87-8033-DEC306051486 Q38769323-87658299-B8E5-4515-9112-982FF180ABF3 Q38872029-B756C393-0557-44EB-9363-2ED4DA0C49B9 Q38878220-2AC15EC0-4367-4AF0-8A7C-2F9866DC7EC6 Q38884006-2042193F-1474-4EFC-8A9C-C1FDD2AA6D74 Q38946224-DD8088E9-D063-4F66-ABEA-524FA4D39466 Q39134087-2DE79600-5F99-4436-B3BE-A9C47847A214 Q39404029-66ED0ED9-A81C-4DCD-ADCD-E39A73AE140C Q40363516-835B9215-1BEF-493F-831A-A98C5C6C7B0C Q42156598-F3D80195-291A-4CAA-9B86-EF6FDD2F1A45 Q42482469-8855056D-6473-4E52-9781-63B1AB08D7F6 Q45246957-09C52518-8393-4127-A4FD-1A30A4505B43

P2860

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

http://www.wikidata.org/entity/Q34209099

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@ast

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@en

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@nl

type

label

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@ast

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@en

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@nl

prefLabel

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@ast

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@en

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@nl

P1433

Q34209099-C1D9E8D7-2347-43CA-A2FE-4BE3CFF97A03

P1476

Q34209099-2AEF75AB-F2F9-4CF9-9170-EA62B70DF1A2

P2093

Q34209099-148E5916-4F66-4BDA-B20D-FF4EAD199CE1

Q34209099-19D773AC-B24D-4844-A789-49762F92EDA4

Q34209099-21261148-904B-4947-9863-A2F187F094FB

Q34209099-258C25CC-6716-4962-BB31-343E5E6FB3E8

Q34209099-59200EE4-E75C-4BEB-BC7E-5ABF1EB82B55

Q34209099-5C88D7C9-A668-48F8-A5D0-26342B2373D8

P2860

Q34209099-0EC5F604-D64D-493C-A6A4-324A45931651

Q34209099-141F9909-E266-427F-9868-A637F328E87D

Q34209099-235189AD-CA59-4E53-9971-A89A624260D3

Q34209099-25856698-B122-4226-8D01-342B1DB511F6

Q34209099-28C510C0-5754-4C63-8BEF-FD7F36D03C24

Q34209099-2B6480DA-C3D5-45BA-B319-3EC71CC30BD2

Q34209099-38109E32-3DE0-4A0C-8BE7-439EF669BA28

Q34209099-3A26164D-0B6D-4A48-8E75-990A8EE261D0

Q34209099-3D6EDEA7-4397-48CD-8BCC-225668BEC6C9

Q34209099-3DD51010-476C-4726-9FF0-438594E8DD16

P304

Q34209099-6E85F7CF-EDCE-45E6-B705-5A625CA9B74E

P31

Q34209099-068FA9BA-2631-44B8-BF32-9605674671E8

P356

Q34209099-5921CE89-BCDA-4BA0-8561-2656DF04571E

P433

Q34209099-269DFDB1-F797-4E14-9C30-CFC008400860

P478

Q34209099-68C55734-613B-43B6-B2DD-D2717E56DAB2

P577

Q34209099-AACC182D-7E20-4E68-A904-3CA7C7DA30B3

P5875

Q34209099-994F02ED-779F-4FB7-ABF4-AF5FB2233F7E

P698

Q34209099-BB715EC4-CDFB-4808-8FA1-3E13CD6D551C

P932

Q34209099-D1CD40CE-A8A6-4211-9F8D-CAEA75DB6F5B

P356

P1433

Genes & Development

P1476

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

@en

P2093

Carla P Martins

http://www.w3.org/2001/XMLSchema#string

Daniel Garcia

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Passegué

http://www.w3.org/2001/XMLSchema#string

Gerard I Evan

http://www.w3.org/2001/XMLSchema#string

Lamorna Brown Swigart

http://www.w3.org/2001/XMLSchema#string

Matthew R Warr

http://www.w3.org/2001/XMLSchema#string

P2860

Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein

Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.

Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase

An essential function of the extreme C-terminus of MDM2 can be provided by MDMX

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

The genetics of the p53 pathway, apoptosis and cancer therapy.

MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation

Mutual dependence of MDM2 and MDMX in their functional inactivation of p53

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

P304

1746-1757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GAD.16722111

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51581657

http://www.w3.org/2001/XMLSchema#string

P698

21852537

http://www.w3.org/2001/XMLSchema#string

P932

3165938

http://www.w3.org/2001/XMLSchema#string